Teva

The Tel Aviv Stock Exchange opened the week with slight gains on Monday, led by Electra Real Estate surging 14.22%, while Gilat dropped 8.04%.

Leader Capital Markets raised Teva's target price to $50 with a "Buy" rating following FDA approval for Weltruza, stronger financials, and an investment-grade credit rating recovery across major agencies.

Teva Pharmaceutical shares reached a ten-decade high following FDA approval for WELTRUZA. The milestone underscores the company's successful turnaround under CEO Richard Francis.

Wall Street finished the week with mixed trends as Israeli-linked stocks made headlines. Teva surged to a yearly high following FDA approval for its schizophrenia drug WELTRUZA, SimilarWeb outlined its new CEO compensation package, and Citi downgraded Nova.

Teva announced US FDA approval for WELTRUZA, a once-monthly extended-release injectable treatment for adults with schizophrenia, boosting its shares in pre-market New York trading.

Britain's Royal College of Nursing severed commercial ties with Teva UK under activist pressure, while the Israeli pharmaceutical giant continues robust financial growth and pipeline advancements.

S&P Global Ratings upgraded Teva's long-term credit rating to investment grade BBB- with a stable outlook. This is Teva's third upgrade in recent months, following similar moves by Fitch and Moody's.

Teva reported positive results in a clinical trial for the treatment of celiac disease. The trial met its primary endpoint, demonstrating that the TEV-408 antibody prevents intestinal damage.

The company reports success in a clinical trial for a drug that blocks an inflammatory protein. The treatment is intended for two different conditions and is expected to advance to later development stages soon.

Biomedical company BioXcel has filed for bankruptcy protection. Pharma giant Teva is serving as the stalking horse bidder in the auction, on the way to a potential acquisition of revolutionary AI-based drugs.

The Turkish Competition Authority has opened an investigation into the pharmaceutical company Teva on suspicion of taking steps to limit competition in the generic drug market, including through the strategic use of patent procedures and the presentation of allegedly misleading information to health authorities. The company stated: "This is a process concerning the Copaxone drug from the past, and...

In Globes' weekly section, we analyzed the performance of prominent Israeli stocks on Wall Street. Wix stock has doubled its value since the June low, driven by the rapid growth of its subsidiary, Base44. Teva reached a decade-high peak thanks to a debt rating upgrade and accelerated FDA approval. Meanwhile, the deal to sell LivePerson is delayed due to a lack of a majority among all shareholders.

The FDA has accepted for review Teva's application for the approval of Aukopipam for the treatment of children with Tourette syndrome and has granted it an accelerated pathway. If approved, it could be the first drug in the field with a new mechanism of action in over 50 years.

Following the October 7 events, the demand for mental health services in the Bedouin Negev society has surged. Amidst a lack of resources, therapists are facing increasing threats, prompting the development of a new professional safety protocol.

Dual listing allows a company's stock to be traded on two or more exchanges simultaneously. We explain how it works, what rights investors retain, and why this strategy benefits both businesses and shareholders.

Following Teva's mixed results, the market is focusing on forward-looking guidance rather than just current figures. This week, attention turns to reports from Tower, Nova, Bezeq, El Al, and Nice.

The last trading week on the Tel Aviv Stock Exchange saw sharp contrasts as Teva jumped 13.47%, while chip manufacturers Tower and Nova suffered significant losses amid market volatility.

A bus company prepares to acquire a competitor, US interest rates remain unchanged, and Teva is on track for the S&P 500 — these are the top news stories of the week on Ice.

Tech giants reported, and both are increasing AI investments, but the market rewarded only Microsoft. Teva jumped 10.2% after strong reports. Still, dual-listed stocks are expected to fall today.

Teva's transformation from a generics manufacturer to an originator drug developer has pushed its market cap above $40 billion. The company is planning a direct listing in New York to facilitate its inclusion in the S&P 500 index.

The Tel Aviv Stock Exchange closed Wednesday's session with losses across major indices. While the market trend was negative, Teva shares saw a significant rally, whereas Opko Health and Yohananof recorded notable declines.

Teva reported $4.1 billion in revenue, exceeding analyst forecasts. Net profit was 2 cents per share versus the expected 11 cents, due to Emalex acquisition costs. The company raised its annual revenue guidance, and shares are up over 4% in Tel Aviv.